GLP-1 acts on habenular avoidance circuits to control nicotine intake.
Nat Neurosci · 2017
Last updated 2026-05-28In a mouse study, nicotine triggered GLP-1 neurons in the brain, and two GLP-1 drugs—sitagliptin and exenatide—reduced nicotine intake by 20% and 30%, respectively. When researchers activated these neurons directly, nicotine use also dropped. Mice lacking GLP-1 receptors consumed more nicotine than normal mice. The study suggests GLP-1 may act as a 'satiety sensor' for nicotine, signaling the brain to limit intake before unpleasant effects occur.
AI summary of the abstract below.
| Journal | Nat Neurosci, 2017 |
|---|---|
| Citations | 157 |
| Relative citation ratio | 6.95 |
| NIH percentile | 95 |
| Molecules | — |
| Conditions studied | Opioid Use Disorder, Smoking Cessation |
Abstract
Tobacco smokers titrate their nicotine intake to avoid its noxious effects, sensitivity to which may influence vulnerability to tobacco dependence, yet mechanisms of nicotine avoidance are poorly understood. Here we show that nicotine activates glucagon-like peptide-1 (GLP-1) neurons in the nucleus tractus solitarius (NTS). The antidiabetic drugs sitagliptin and exenatide, which inhibit GLP-1 breakdown and stimulate GLP-1 receptors, respectively, decreased nicotine intake in mice. Chemogenetic activation of GLP-1 neurons in NTS similarly decreased nicotine intake. Conversely, Glp1r knockout mice consumed greater quantities of nicotine than wild-type mice. Using optogenetic stimulation, we show that GLP-1 excites medial habenular (MHb) projections to the interpeduncular nucleus (IPN). Activation of GLP-1 receptors in the MHb-IPN circuit abolished nicotine reward and decreased nicotine intake, whereas their knockdown or pharmacological blockade increased intake. GLP-1 neurons may therefore serve as 'satiety sensors' for nicotine that stimulate habenular systems to promote nicotine avoidance before its aversive effects are encountered.
Verbatim abstract via PubMed 28368384 ↗